Blood Glucose Screening in Patients With Advanced Periodontits: the Role of Specialist Periodontal Care in Identifying Hyperglycaemia and Supporting Patient Centered Treatment

Sponsor
Folktandvården Stockholms län AB
Study ID
NCT07426224
Status
Enrolling By Invitation

Conditions

  • Diabetes (DM)
  • Hyperglycaemia
  • Periodontitis Stage III
  • Periodontitis Stage IV
  • Prediabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Selective screening of blood glucose/HbA1c — OTHER
    Selective screening for hyperglycaemia in dental setting is a new routine that has not been introduced in Folktandvården Stockholm.

Study Details

Periodontitis is a chronic inflammatory disease and individuals with advanced periodontitis have an increased risk of hyperglycaemia. Bacterial plaque, smoking and elevated blood glucose levels are considered key modifiable risk factors for periodontal disease progression. Conventional periodontal care aims to remove and control bacterial deposits and to smoking cessation. Despite the bidirectional relationship, where periodontitis may also contribute to impaired glycaemic control, glycaemic status is rarely niether assessed nor adressed in dental care. The aim of this project is to implement and evaluate routine blood glucose testing as part of the periodontal examination in specialist dental care. Patients diagnosed with advanced periodontitis (Stage III or IV according to the current classification) will be offered capillary blood glucose testing during their periodontal assessment. The objectives of this study are to determine the prevalence of hyperglycaemia among patients with advanced periodontitis and to evaluate clinician-reported and patient-reported experiences of routine blood glucose testing as part of the periodontal assesment in specialist periodontal care.

Key Dates

First listed
Feb 23, 2026
Start date
Mar 13, 2026
Status verified
May 2026
Primary completion
Mar 1, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
300 participants (estimated)

Primary Outcome Measure

HbA1c mmol/mol [ Time Frame: The bloodsampling is done chair-side and is analysed immediatley with a Point-of-Care device meaning the procedure is limited to maximum 5 minutes. ]

Related Studies